Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), MacroGenics (MGNX) and HUTCHMED (HCM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Viatris (VTRS – Research Report), MacroGenics (MGNX – Research Report) and HUTCHMED (HCM – Research Report).

Viatris (VTRS)

BMO Capital analyst Gary Nachman maintained a Buy rating on Viatris today and set a price target of $16.00. The company’s shares closed last Tuesday at $10.22, close to its 52-week low of $9.45.

According to TipRanks.com, Nachman is ranked 0 out of 5 stars with an average return of -5.7% and a 43.2% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Phathom Pharmaceuticals, and Ionis Pharmaceuticals.

Viatris has an analyst consensus of Hold, with a price target consensus of $11.83.

See the top stocks recommended by analysts >>

MacroGenics (MGNX)

SVB Securities analyst Jonathan Chang maintained a Buy rating on MacroGenics today and set a price target of $12.00. The company’s shares closed last Tuesday at $4.94, close to its 52-week low of $2.13.

According to TipRanks.com, Chang is ranked 0 out of 5 stars with an average return of -10.7% and a 31.0% success rate. Chang covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Harpoon Therapeutics, and Revolution Medicines.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for MacroGenics with a $12.86 average price target, a 179.6% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $8.00 price target.

HUTCHMED (HCM)

In a report released today, Paul Choi from Goldman Sachs maintained a Hold rating on HUTCHMED, with a price target of $16.00. The company’s shares closed last Tuesday at $13.02, close to its 52-week low of $8.41.

According to TipRanks.com, Choi is a 4-star analyst with an average return of 8.6% and a 51.8% success rate. Choi covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Springworks Therapeutics, and Phathom Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for HUTCHMED with a $16.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VTRS:

• NVIDIA and Partners Build Out Universal Scene Description to Accelerate Industrial Metaverse and Next Wave of AI
• Cyclo Therapeutics (CYTH) Receives a Buy from Maxim Group
• Echelon Wealth Partners Keeps Their Buy Rating on Osino Resources (OSIIF)
• Retransmission – Endeavour Silver Announces Q2 2022 Financial Results; Raises 2022 Production Guidance
• Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Syros Pharmaceuticals (SYRS)